5 results
The primary objective for this study is:• To explore the usefulness of [F-18]RGD-K5 PET/CT to predict efficacy or early response toAvastin® (the anti-angiogenesis drug) plus chemotherapy treatment before the full courseof treatment is completedThe…
Primary: Safety and tolerability of fingolimod 0,5 mg.Secundairy: Efficacy and quality of life.
To assess the antibody response after SARS-CoV-2 vaccination in people >=16 years and children with Down Syndrome. Part 2To assess the antibody response after a third SARS-CoV-2 vaccination in adults and children with Down Syndrome and to…
PRIMARY OBJECTIVE: -To assess the antibody response after mRNA (Pfizer, Moderna) SARS-CoV-2 vaccination in children with cancerSECONDARY OBJECTIVES:To assess in children with cancer after SARS-CoV 2 vaccination:- durability of the antibody response…
The purpose of this study is to seek regulatory approval for use of fingolimod in a pediatric population with MS aged 10 to less than 18 years old. This study is conducted in line with the Pediatric Investigational Plan agreed with the EMA (under EU…